Search Orphan Drug Designations and Approvals
-
Generic Name: | (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide |
---|---|
Date Designated: | 12/14/2017 |
Orphan Designation: | Treatment of C3 glomerulopathy (C3G) |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Alexion Pharmaceuticals, Inc 300 George Street New Haven, Connecticut 06511 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-